AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03414892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Globalagliatin Hydrochloride
Description: once daily, oral
Study NCT00573794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: adalimumab prefilled syringes administered as subcutaneous injection EW or EOW
Study NCT02999490 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: 18F-FDG is positron emission tomography imaging agent which is already widely used in PET/CT examination.
Study NCT00434135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine plus pemetrexed, paclitaxel plus gemcitabine
Description: gemcitabine 1,250 mg/sqm days 1\&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1\&8
Study NCT00434135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine plus pemetrexed, paclitaxel plus gemcitabine
Description: gemcitabine 1,250 mg/sqm days 1\&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1\&8
Study NCT00639938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: 200 mg Nevirapine tablet
Study NCT00639938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: 200 mg Nevirapine tablet
Study NCT00639938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIV immune globulin solution
Description: 5% intravenous HIV immune globulin solution
Study NCT02584192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: entailing an early home-based CR program
Description: enter the early outpatient phase of CR program. The progressive exercise training of this phase was performed without supervision after their discharge. The CR program consisted of a five-minute warm-up period (stretching), a twenty-minute aerobic exercise (walking or trotting, gymnastics), and a five-minute cooling-down period (stretching)
Study NCT02584192 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: enter the usual care program
Description: enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
Study NCT01563887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DD.com
Description: Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
Study NCT01563887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DD.com + MI
Description: Prior to starting and immediately after finishing the DiabetesDriving.com internet intervention, a one hour motivational interview will be conducted with participants. Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
Study NCT01044186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICL670
Study NCT03961711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
Study NCT03961711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Clinic Visit
Description: Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
Study NCT01116544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES Therapy (assisted movement and enhanced sensation)
Description: Each subject will receive 30 sessions of AMES therapy in the clinic. Each session will consist of 10 min of functional testing (i.e., passive motion and strength tests) followed by 30 min of grasp therapy using the AMES device. One group of subjects will receive AMES therapy only with joint torque biofeedback (without EMG feedback), and the other group will receive AMES therapy with EMG biofeedback. While all test subjects should attempt to open the hand when the grasp mechanism is opening and close the hand when the mechanism is closing, the biofeedback information provided to aid a subject will differ for the 2 subject groups.
Study NCT04416880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press Tack Needle Acupuncture
Description: Seirin Pyonex Press Tack Needle 0.20 x 0.60 mm for SI1 Shaoze acupuncture point Seirin Pyonex Press Tack Needle 0.20 x 0.90 mm for CV17 Danzhong acupuncture point
Study NCT04416880 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Press Tack Needle Acupuncture
Description: Seirin Pyonex Press Tack Needle 0.20 x 0.60 mm for SI1 Shaoze acupuncture point Seirin Pyonex Press Tack Needle 0.20 x 0.90 mm for CV17 Danzhong acupuncture point
Study NCT04396899 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EHM implantation
Description: Implantation of EHM on dysfunctional left or right ventricular myocardium in patients with HFrEF (EF \<35%).
Study NCT05268406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Scan System
Description: Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake approximately 48 hours prior to the planned C-Scan procedure start. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
Study NCT00930215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H
Description: Oral gelatin capsule
Study NCT00930215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H
Description: Oral HPMC capsule
Study NCT03449264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological collection
Description: * Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.~* Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out.
Study NCT01725750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright White Light (BWL)
Description: Participants will self-administer bright white light daily. Litebooks used for Bright White Light and Dim Red Light are identical except for the light which they emit. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box.
Study NCT01725750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dim Red Light (DRL)
Description: A device that appears identical to BWL Litebook but that uses red LEDs emitting DRL. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box.
Study NCT00982904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole/Placebo
Study NCT00982904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fexinidazole/Placebo
Study NCT02542072 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: contact lens
Study NCT02542072 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: samfilcon A
Description: contact lens
Study NCT04241965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-214870
Description: Tablet(s)
Study NCT04241965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPC-214870
Description: Tablet(s)
Study NCT04241965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet(s)
Study NCT04241965 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet(s)
Study NCT01502904 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Study NCT02393157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal ARA-C
Description: Will be given intrathecally for both prophylaxis and treatment of CNS disease.
Study NCT02393157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.
Study NCT02393157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.
Study NCT02393157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).
Study NCT01220076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Study NCT01502904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Study NCT01502904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin 20mg/day after DES implantation
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Study NCT01502904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitavastatin 2mg/day after DES implantation
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Study NCT01502904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-ARB /day after DES implantation
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Study NCT01502904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eposartan 600mg/day after DES implantation
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Study NCT01032148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.
Study NCT02901431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
Study NCT02901431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5285119
Description: Participants received age-adjusted total daily oral dose approximately equivalent to the adult doses of either 4 mg/d or 10 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
Study NCT00289107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Rotating Platform (RP) Cruciate Substituting Knee System
Study NCT00289107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: Fixed Cruciate Substituting Knee System
Study NCT03414892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, oral
Study NCT04055428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril, Valsartan 97-103 mg Oral Tablet
Description: The subject will be randomized, in a double-blind manner to sacubitril/valsartan 97/103 mg twice daily for a period of 12 weeks.
Study NCT04055428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160 mg
Description: The subject will be randomized, in a double-blind manner to valsartan 160 mg twice daily for a period of 12 weeks.
Study NCT04055428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous Glucose Tolerance Test
Description: An assessment of the insulin sensitivity will be done using the IVGTT, at baseline and after 12 weeks of pharmacological interventions.
Study NCT04055428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Glucose Tolerance Test
Description: An assessment of the insulin sensitivity will be done using the IVGTT, at baseline and after 12 weeks of pharmacological interventions.
Study NCT04055428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Meals
Description: Participants will consume the standardized study mixed meal for the assessment of postprandial GLP-1 response to the meal.
Study NCT04230863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroplasticity-based Computerized Cognitive Remediation
Description: The nCCR has two major components: Bottom up and Top down training. Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization.
Study NCT00413959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE®
Description: 1.6 mg/m\^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
Study NCT04165148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Impact Laparoscopy
Description: Low Impact Laparoscopy is a minimally invasive technique that combines low pressure insufflation (with the iFS AirSeal® system) and microcoelioscopy (with specific microtrocards and laparoscopic instruments).
Study NCT04165148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopy
Description: conventional laparoscopy
Study NCT00413959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
Study NCT00413959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 400 mg/m\^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
Study NCT00413959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decadron
Description: 40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23
Study NCT02288273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bydureon
Description: Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks.
Study NCT02288273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04165148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) for Pain
Description: The patient evaluates her pain using an VAS scale on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with VAS scale) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an VAS.
Study NCT04165148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual Analog Scale (VAS) for Pain
Description: The patient evaluates her pain using an VAS scale on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with VAS scale) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an VAS.
Study NCT03913156 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: B2970 Metabolic Texture Modified Protein Substitute
Description: The study product is a powdered phe-free protein substitute supplemented with long chain polyunsaturated fatty acids (LCP's), containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements and has been designed for use in the management of proven PKU in children aged 6 months to 5 years.
Study NCT04055428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Meals
Description: Participants will consume the standardized study mixed meal for the assessment of postprandial GLP-1 response to the meal.
Study NCT04055428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise capacity VO2 maximum determination
Description: Each participant's maximal oxygen capacity will be determined using modified Bruce treadmill protocol.
Study NCT01997463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supervised asthma therapy in schools
Description: Therapy observed daily in school. Asthma education by American Lung Association
Study NCT03598387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated peritoneal dialysis
Description: The prescription of automated peritoneal dialysis:~* The first 48-72 hours dose: 0.8-2.0 liter exchange with 1-2 hour-cycle (8-36 liters per day); After initial 48-72 hours, 1.0-2.5L exchange with 2-6 hour-cycle (at least 8 liters per day), if the acidosis, hyperkalemia and pulmonary edema are corrected.~* The minimal target weekly Kt/V is 2.1-3.5/W.
Study NCT03598387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent hemodialysis
Description: Intermittent hemodialysis will be performed 3-4h of each session and 2-5 times per week. The prescription will be adjusted based on patients' conditions to ensure spKT/V≥1.3.
Study NCT01230879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EFR and TDM
Description: EFR : Pulmonary function test TDM : tomodensitometry
Study NCT02109341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel bound albumine
Study NCT00630331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell culture-derived influenza vaccine
Description: One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle.
Study NCT00630331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Egg-derived influenza virus vaccine
Description: One dose (0.5 mL) of the trivalent egg-derived influenza virus vaccine, administered in the deltoid muscle.
Study NCT04055428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise capacity VO2 maximum determination
Description: Each participant's maximal oxygen capacity will be determined using modified Bruce treadmill protocol.
Study NCT03104660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CE certified mitral valve repair systems
Description: Patients receive a transcatheter mitral valve repair with CE certified transcatheter mitral repair systems.
Study NCT01785173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic-guided gauze pledgetting
Description: By using a transnasal endoscope as a guide and a biopsy forceps, a gauze strip soaked with decongestant and anesthesia will be delivered to a selected nasal meatus chosen by anterior rhinoscopy.
Study NCT04165148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saint-Antoine Pain Questionnaire (QDSA)
Description: The patient evaluates her pain using an QDSA questionnaire on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with QDSA questionnaire) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an QDSA questionnaire.